[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CL2021001613A1 - Substituted oxopyridine derivatives - Google Patents

Substituted oxopyridine derivatives

Info

Publication number
CL2021001613A1
CL2021001613A1 CL2021001613A CL2021001613A CL2021001613A1 CL 2021001613 A1 CL2021001613 A1 CL 2021001613A1 CL 2021001613 A CL2021001613 A CL 2021001613A CL 2021001613 A CL2021001613 A CL 2021001613A CL 2021001613 A1 CL2021001613 A1 CL 2021001613A1
Authority
CL
Chile
Prior art keywords
thrombotic
oxopyridine derivatives
substituted oxopyridine
substituted
derivatives
Prior art date
Application number
CL2021001613A
Other languages
Spanish (es)
Inventor
Röhrig Susanne
Essig Sebastian
Ellerbrock Pascal
Anlauf Sonja
Neubauer Thomas
Hillisch Alexander
Meier Katharina
Heitmeier Stefan
Tersteegen Adrian
Schäfer Martina
Stampfuss Jan
Lang Dieter
Wang Hongping
Zou Zengqiang
Meng Xianghai
Matthias Gericke Kersten
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of CL2021001613A1 publication Critical patent/CL2021001613A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La invención se refiere a derivados de oxopiridina sustituidos y a procesos para su preparación, y también a su uso para preparar medicamentos para el tratamiento y/o la profilaxis de enfermedades, en particular trastornos vasculares, preferentemente trastornos trombóticos o tromboembólicos y/o complicaciones trombóticas o tromboembólicas.The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular vascular disorders, preferably thrombotic or thromboembolic disorders and/or thrombotic or thrombotic complications. thromboembolic.

CL2021001613A 2018-12-21 2021-06-17 Substituted oxopyridine derivatives CL2021001613A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2018122825 2018-12-21

Publications (1)

Publication Number Publication Date
CL2021001613A1 true CL2021001613A1 (en) 2021-12-03

Family

ID=69143542

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021001613A CL2021001613A1 (en) 2018-12-21 2021-06-17 Substituted oxopyridine derivatives

Country Status (22)

Country Link
EP (1) EP3898633A1 (en)
JP (1) JP2022514303A (en)
KR (1) KR20210106504A (en)
CN (1) CN113474348A (en)
AR (1) AR117435A1 (en)
AU (1) AU2019407909B2 (en)
BR (1) BR112021009435A2 (en)
CA (1) CA3124220A1 (en)
CL (1) CL2021001613A1 (en)
CO (1) CO2021007908A2 (en)
CR (1) CR20210342A (en)
DO (1) DOP2021000128A (en)
EA (1) EA202191764A1 (en)
EC (1) ECSP21043895A (en)
IL (1) IL283990A (en)
JO (1) JOP20210161A1 (en)
MA (1) MA54521A (en)
MX (1) MX2021007508A (en)
PE (1) PE20211790A1 (en)
SG (1) SG11202104384PA (en)
TW (1) TW202039510A (en)
WO (1) WO2020127504A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL300463A (en) * 2018-03-15 2023-04-01 Bayer Pharma AG Preparative process of two 4-{[(2s)-2-{4-[5-chloro-2-(1h-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2h)-yl}butanoyl]amino}-2-fluorobenzamide derivatives
CN114105881B (en) 2020-08-31 2024-01-26 沈阳海诺威医药科技有限公司 Platelet aggregation inhibitor, and preparation method and application thereof
EP4304561A1 (en) 2021-03-09 2024-01-17 Bayer Aktiengesellschaft Pharmaceutical dosage forms comprising (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5- dioxo-14-(trifluoromethyl)-32h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)- dibenzenaheptaphane-74-carboxamide
KR20230155505A (en) 2021-03-09 2023-11-10 바이엘 악티엔게젤샤프트 (4S)-24-Chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoro-methyl)-32H-6-aza-3(4,1 )-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-5 crystalline form of dibenzenaheptaphane-74-carboxamide
WO2022189280A1 (en) 2021-03-09 2022-09-15 Bayer Aktiengesellschaft Solvates of (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoro-methyl)-32 h-6- aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide
CN114560754A (en) * 2022-02-25 2022-05-31 滁州学院 Preparation method of alkyl alcohol
WO2024223790A1 (en) * 2023-04-28 2024-10-31 Basf Se Use of alkyl 4-alkoxypentanoates as aroma chemicals
CN116874469B (en) * 2023-09-06 2023-11-10 成都施贝康生物医药科技有限公司 Oxo-pyridine compound, intermediate, preparation method and application thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
DE102006032824A1 (en) * 2006-07-14 2008-01-17 Bayer Healthcare Ag Substituted indazoles
EP2091947A2 (en) 2006-12-20 2009-08-26 Takeda San Diego, Inc. Glucokinase activators
US9809545B2 (en) 2013-03-27 2017-11-07 Merck Sharp & Dohme Corp. Factor XIa inhibitors
TWI633089B (en) * 2013-03-28 2018-08-21 拜耳製藥股份有限公司 Substituted oxopyridine derivatives
EP3024822B1 (en) 2013-07-23 2017-05-03 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives and their use as factor xia and plasma kallikrein inhibitors
EP3063150B1 (en) 2013-10-30 2017-11-22 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
US10071995B2 (en) 2014-09-24 2018-09-11 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
ES2713624T3 (en) 2014-09-24 2019-05-23 Bayer Pharma AG Substituted oxopyridine derivatives
ES2722425T3 (en) 2014-09-24 2019-08-12 Bayer Pharma AG (2H) -2-Oxopyridines as inhibitors of factor XIa for the treatment of thrombotic diseases
ES2722423T3 (en) * 2014-09-24 2019-08-12 Bayer Pharma AG Substituted oxopyridine derivatives
ES2712886T3 (en) * 2014-09-24 2019-05-16 Bayer Pharma AG Derivatives of pyridobenzazepine and pyridobenzazocine that inhibit factor XIa
US10414731B2 (en) 2014-09-24 2019-09-17 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
CN107428689A (en) * 2015-03-19 2017-12-01 拜耳制药股份公司 As the oxo pyridine derivative for treating thrombotic factor XI, plasma thromboplastin antecedent A inhibitor
JO3703B1 (en) 2015-07-09 2021-01-31 Bayer Pharma AG Substituted oxopyridine derivatives
EP3344618A1 (en) 2015-09-04 2018-07-11 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives

Also Published As

Publication number Publication date
ECSP21043895A (en) 2021-07-30
CA3124220A1 (en) 2020-06-25
EP3898633A1 (en) 2021-10-27
MX2021007508A (en) 2021-08-05
PE20211790A1 (en) 2021-09-09
IL283990A (en) 2021-07-29
CO2021007908A2 (en) 2021-07-19
DOP2021000128A (en) 2021-09-30
CR20210342A (en) 2021-08-09
CN113474348A (en) 2021-10-01
AU2019407909A1 (en) 2021-05-27
TW202039510A (en) 2020-11-01
AU2019407909B2 (en) 2023-05-25
KR20210106504A (en) 2021-08-30
MA54521A (en) 2022-03-30
AR117435A1 (en) 2021-08-04
BR112021009435A2 (en) 2021-08-17
EA202191764A1 (en) 2021-10-22
WO2020127504A1 (en) 2020-06-25
SG11202104384PA (en) 2021-05-28
JOP20210161A1 (en) 2023-01-30
JP2022514303A (en) 2022-02-10

Similar Documents

Publication Publication Date Title
CL2021001613A1 (en) Substituted oxopyridine derivatives
ECSP18001308A (en) SUBSTITUTE OXOPYRIDINE DERIVATIVES
CR20150476A (en) OXOPYRIDINE SUBSTITUTED DERIVATIVES AND ITS USE IN THE TREATMENT OF CARDIOVASCULAR DISORDERS
ECSP20072258A (en) Substituted derivatives of the carboxamide dihydropyrazolo pyrazine
UY35344A (en) OESTRA-1,3,5 (10), 16-TETRAENE-3-CARBOXAMIDS
CO2019002361A2 (en) 1-arylnaphthyridine-3-substituted 7-carboxamides and their use
UY37671A (en) N-ARILETIL-2-AMINOQUINOLIN-4-SUBSTITUTED CARBOXAMIDS AND THEIR USE
ECSP24024658A (en) SUBSTITUTED S-ALANINATE DERIVATIVES
CO2019011285A2 (en) N-arylethyl-2-arylquinoline -4-substituted carboxamides and their use
NI201500168A (en) SUBSTITUTE BENZOXAZOLES